Correlation Between Aceragen and Checkpoint Therapeutics

Can any of the company-specific risk be diversified away by investing in both Aceragen and Checkpoint Therapeutics at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Aceragen and Checkpoint Therapeutics into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Aceragen and Checkpoint Therapeutics, you can compare the effects of market volatilities on Aceragen and Checkpoint Therapeutics and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Aceragen with a short position of Checkpoint Therapeutics. Check out your portfolio center. Please also check ongoing floating volatility patterns of Aceragen and Checkpoint Therapeutics.

Diversification Opportunities for Aceragen and Checkpoint Therapeutics

-0.37

Correlation Coefficient

Aceragen  Checkpoint Therapeutics

Very good diversification

The 3 months correlation between Aceragen and Checkpoint is -0.37. Overlapping area represents the amount of risk that can be diversified away by holding Aceragen and Checkpoint Therapeutics in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Checkpoint Therapeutics and Aceragen is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Aceragen are associated (or correlated) with Checkpoint Therapeutics. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Checkpoint Therapeutics has no effect on the direction of Aceragen i.e., Aceragen and Checkpoint Therapeutics go up and down completely randomly.

Pair Corralation between Aceragen and Checkpoint Therapeutics

Given the investment horizon of 90 days Aceragen is expected to under-perform the Checkpoint Therapeutics. In addition to that, Aceragen is 1.95 times more volatile than Checkpoint Therapeutics. It trades about -0.11 of its total potential returns per unit of risk. Checkpoint Therapeutics is currently generating about 0.01 per unit of volatility. If you would invest  698.00  in Checkpoint Therapeutics on October 7, 2024 and sell it today you would lose (333.00) from holding Checkpoint Therapeutics or give up 47.71% of portfolio value over 90 days.

Time Period	3 Months [change]
Direction	Moves Against
Strength	Insignificant
Accuracy	26.41%
Values	Daily Returns

Aceragen  vs.  Checkpoint Therapeutics

Aceragen

Risk-Adjusted Performance

0 of 100

Very Weak

Over the last 90 days Aceragen has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of very healthy technical and fundamental indicators, Aceragen is not utilizing all of its potentials. The recent stock price disarray, may contribute to short-term losses for the investors.

Checkpoint Therapeutics

Risk-Adjusted Performance

12 of 100

Good

Compared to the overall equity markets, risk-adjusted returns on investments in Checkpoint Therapeutics are ranked lower than 12 (%) of all global equities and portfolios over the last 90 days. In spite of comparatively unfluctuating basic indicators, Checkpoint Therapeutics unveiled solid returns over the last few months and may actually be approaching a breakup point.

Pair Trading with Aceragen and Checkpoint Therapeutics

The main advantage of trading using opposite Aceragen and Checkpoint Therapeutics positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Aceragen position performs unexpectedly, Checkpoint Therapeutics can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Checkpoint Therapeutics will offset losses from the drop in Checkpoint Therapeutics' long position.

The idea behind Aceragen and Checkpoint Therapeutics pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Content Syndication module to quickly integrate customizable finance content to your own investment portal.